目前，先降低病毒负荷、再免疫调节治愈的路径已经达成共识。由此可见，我们依然需要新的更强的DAA药物。在慢性乙肝治疗的新药开发上，我国政府部门的态度则更加务实。如中国国家药监局药品审评中心（CDE）最近批准了已知HBVDNA复制作用更加明显的NA类新药 ...

GSK is prioritizing development of its hepatitis B treatment bepirovirsen as the pharma ends work on another potential ...

近年来，国内外大量研究均已表明，HBV在肝内形成的共价闭合环状DNA（HBV cccDNA）库的持续存在与HBV慢性持续性感染以及慢性乙型肝炎（CHB）难以治愈密切相关。HBV cccDNA的彻底清除不仅是判定HBV感染彻底治愈的重要指标，也是终止CHB进展为肝硬化、肝细胞癌（HCC ...

因此，目前功能性治愈是CHB治疗的主要终点。 图8. CHB患者获功能性治愈与未获功能性治愈示意图 参考文献： [1] Lok AS, Zoulim F, Dusheiko G, et al. Hepatitis B cure: From discovery to regulatory approval[J]. Hepatology, 2017, 66(4):1296-1313. DOI: ...

The push to cure hepatitis B kicked off in earnest about 10 years ago, when several leading HBV scientists began convening scientific workshops aimed at developing a cure-focused action plan ...

近年来，国内外大量研究均已表明，HBV在肝内形成的共价闭合环状DNA（HBV cccDNA）库的持续存在与HBV慢性持续性感染以及慢性乙型肝炎（CHB）难以治愈 ...

Please provide your email address to receive an email when new articles are posted on . The highest percentages of patients with HBsAg loss were observed in the groups that received xalnesiran ...

Viral hepatitis is a major danger to public health. According to WHO’s 2024 Global Hepatitis Report, viral hepatitis deaths ...

Famciclovir. A prodrug of penciclovir, famciclovir does not have a major role in the treatment of chronic hepatitis B because of its low efficacy compared with lamivudine. Adefovir dipivoxil.

and HBV DNA after 24 weeks' treatment to below the lower limit of detection in people with chronic hepatitis B, raising hopes that it could offer permanent cure, allowing safe termination of ...

Chronic HBV remains a global health issue with a high unmet medical need since there is no cure available. The current standard of care requires lifelong antiviral therapy to maintain control of ...